- Home
- CMMB vs TLPH Comparison
CMMB vs TLPH Comparison
Compare CMMB & TLPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMMB
- TLPH
- Stock Information
- Founded
- CMMB 2004
- TLPH 2005
- Country
- CMMB Israel
- TLPH United States
- Employees
- CMMB N/A
- TLPH N/A
- Industry
- CMMB Biotechnology: Pharmaceutical Preparations
- TLPH Biotechnology: Pharmaceutical Preparations
- Sector
- CMMB Health Care
- TLPH Health Care
- Exchange
- CMMB Nasdaq
- TLPH Nasdaq
- Market Cap
- CMMB 15.8M
- TLPH 15.7M
- IPO Year
- CMMB N/A
- TLPH 2011
- Fundamental
- Price
- CMMB $1.51
- TLPH $0.78
- Analyst Decision
- CMMB Strong Buy
- TLPH Strong Buy
- Analyst Count
- CMMB 3
- TLPH 2
- Target Price
- CMMB $5.67
- TLPH $4.50
- AVG Volume (30 Days)
- CMMB 231.4K
- TLPH 85.2K
- Earning Date
- CMMB 11-07-2024
- TLPH 11-06-2024
- Dividend Yield
- CMMB N/A
- TLPH N/A
- EPS Growth
- CMMB N/A
- TLPH N/A
- EPS
- CMMB N/A
- TLPH N/A
- Revenue
- CMMB N/A
- TLPH $398,000.00
- Revenue This Year
- CMMB N/A
- TLPH N/A
- Revenue Next Year
- CMMB N/A
- TLPH N/A
- P/E Ratio
- CMMB N/A
- TLPH N/A
- Revenue Growth
- CMMB N/A
- TLPH 57.31
- 52 Week Low
- CMMB $0.42
- TLPH $0.43
- 52 Week High
- CMMB $2.55
- TLPH $1.61
- Technical
- Relative Strength Index (RSI)
- CMMB 43.28
- TLPH 36.51
- Support Level
- CMMB $1.29
- TLPH $0.75
- Resistance Level
- CMMB $1.58
- TLPH $0.99
- Average True Range (ATR)
- CMMB 0.15
- TLPH 0.08
- MACD
- CMMB -0.04
- TLPH -0.01
- Stochastic Oscillator
- CMMB 39.29
- TLPH 22.22
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.